 |
|
Researcher Profile - Gerard J. Marek |
|
|
|
| First Name: | Gerard J. | | Last Name: | Marek | | Advanced Degrees: | M.D., Ph.D. | | Affiliation: | Abbott Laboratories | | Department: | Neuroscience Development | | Street Address 1: | GPRD R48B AP4-1 | | Street Address 2: | 100 Abbott Park Road | | City: | Abbott Park | | State/Province: | IL | | Zip/Postal Code: | 60064-6075 | Country/Territory: | U.S.A. | | Phone: | (847)937-4453 | | Fax: | (847)937-0745 | | Email Address: |  |
Disclosure:
(view policy) |
Member reports the following financial or other potential conflicts of interest: [Last Modified: 17 October 2008]
Work for Abbott Laboratories. |
|
|
View all comments by Gerard J. Marek
|
Drug abuse, Bipolar disorder , Schizophrenia, Depression, multiple sclerosis, Alzheimer's Disease
|
Brain imaging, Clinical trials, Neurotransmission, Pharmacology, Electrophysiology, Glutamatergic transmission, Animal models
|
Aghajanian, G.K. and Marek, G.J. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacol., 36, 589-599, 1997.
Marek, G.J., Wright, R.A., Schoepp, D.D., Monn, J.A. and Aghajanian, G.K. Physiological antagonism between 5-hydroxytryptamine2A and group II metabotropic glutamate receptors in prefrontal cortex. J. Pharmacol. Exp. Ther., 292, 76-87, 2000.
Gewirtz, J.C. and Marek, G.J. Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacol., 23, 569-576, 2000.
Marek, G.J., Wright, R.A., Gewirtz, J.C. and Schoepp, D.D. A major role for thalamocortical terminals in serotonergic hallucinogen receptor function in neocortex. Neurosci., 105, 379-392, 2001.
Marek, G.J., Wright, R.A. and Schoepp, D.D. 5-Hydroxytryptamine2A (5-HT2A) receptor regulation in rat prefrontal cortex: Interaction of a phenethylamine hallucinogen and the metabotropic glutamate2/3 receptor agonist LY354740. Neurosci. Lett., 403, 256-260, 2006.
Zhang, C. and Marek, G.J. Group III metabotropic glutamate receptor agonists selectively suppress excitatory synaptic currents in the rat prefrontal cortex induced by 5-hydroxytryptamine2A receptor activation. J. Pharmacol. Exp. Ther., 320, 437-447, 2007.
Rorick-Kehn, L.M., Johnson, B.G., Burkey, J.L., Wright, R.A., Calligaro, D.O., Marek, G.J., Nisenbaum, E.S., Catlow, J.T., Kingston, A.E., Giera, D.D., Herin, M.F., Monn, J.A., McKinzie, D.L. and Schoepp, D.D. Pharmacological and pharmacokinetic properties of a structurally-novel, potent, selective mGlu2/3 receptor agonist: In vitro characterization of Agonist (-)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic Acid (LY404039). J. Pharmacol. Exp. Ther., 321, 308-317, 2007.
Zhang, C. and Marek, G.J., AMPA receptor involvement in 5-hydroxytryptamine2A receptor mediated prefrontal cortical excitatory synaptic currents and DOI-induced head shakes. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 32, 62-71, 2008.
Marek, G.J., Regulation of rat cortical 5-hydroxytryptamine2A-receptor mediated electrophysiological responses by repeated daily treatment with electroconvulsive shock or imipramine. Eur. Neuropsychopharmacol., 18: 498-507, 2008
Ardayfio, P.A., Benvenga, M.J., Chaney, S.F., Love, P.L., Catlow, Swanson, S.P. and Marek, G.J., The 5-hydroxytryptamine2A receptor antagonist R-(+)-a-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl-4-piperidinemethanol (M100907) attenuates impulsivity after both drug induced impairment (dizocilpine) and enhancement (antidepressant drugs) of Differential-Reinforcement-of Low Rate 72-s behavior in the rat, J. Pharmacol. Exp. Ther., in press, 2008, doi:10.1124/jpet.108.143370.
|
|
|
|
|
|
